Pathogenesis of Pulmonary Fibrosis in Systemic Sclerosis: Lessons from Interstitial Lung Disease (original) (raw)

Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. Steen VD, Medsger TA: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:2437–2444.
    Article CAS PubMed Google Scholar
  2. Steen VD, Medsger TA: Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007, 66:940–944.
    Article PubMed Google Scholar
  3. Fischer A, Meehan RT, Feghali-Bostwick CA, et al.: Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006, 130:976–981.
    Article PubMed Google Scholar
  4. White B: Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003, 29:371–390.
    Article PubMed Google Scholar
  5. Bouros D, Wells AU, Nicholson AG, et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581–1586.
    Article PubMed Google Scholar
  6. Kim DS, Yoo B, Lee JS, et al.: The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:121–127.
    PubMed Google Scholar
  7. Flaherty KR, Travis WD, Colby TV, et al.: Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001, 164:1722–1727.
    CAS PubMed Google Scholar
  8. Bjoraker JA, Ryu JH, Edwin MK, et al.: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157:199–203.
    CAS PubMed Google Scholar
  9. Daniil ZD, Gilchrist FC, Nicholson AG, et al.: A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999, 160:899–905.
    CAS PubMed Google Scholar
  10. Flaherty KR, Mumford JA, Murray S, et al.: Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543–548.
    Article PubMed Google Scholar
  11. Jegal Y, Kim DS, Shim TS, et al.: Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005, 171:639–644.
    Article PubMed Google Scholar
  12. Latsi PI, du Bois RM, Nicholson AG, et al.: Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531–537.
    Article PubMed Google Scholar
  13. • Zappala CJ, Latsi PI, Nicholson AG, et al.: Marginal decline in FVC is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2009 Oct 19 (Epub ahead of print). This article describes findings which suggest that subtle changes in forced vital capacity can predict prognosis and outcome in IPF.
  14. •• Park JH, Kim DS, Park IN, et al.: Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175:705–711. This article discusses one of the few studies comparing prognosis of IPF and CTD-associated ILD.
    Article PubMed Google Scholar
  15. Fischer A, Swigris JJ, Groshong SD, et al.: Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008, 134:601–605.
    Article PubMed Google Scholar
  16. Silver RM, Wells AU: Histopathology and bronchoalveolar lavage. Rheumatology (Oxford) 2008, 47:v62–v64.
    Article Google Scholar
  17. Suga M, Iyonaga K, Okamoto T, et al.: Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000, 162:1949–1956.
    CAS PubMed Google Scholar
  18. Andersen GN, Nilsson K, Pourazar J, et al.: Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med 2007, 101:2199–2206.
    Article PubMed Google Scholar
  19. Harrison NK, Cambrey AD, Myers AR, et al.: Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci (Colch) 1994, 86:141–148.
    CAS Google Scholar
  20. Prasse A, Pechkovsky DV, Toews GB, et al.: CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007, 56:1685–1693.
    Article CAS PubMed Google Scholar
  21. Bolster MB, Ludwicka A, Sutherland SE, et al.: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997, 40:743–751.
    Article CAS PubMed Google Scholar
  22. Antoniou KM, Mamoulaki M, Malagari K, et al.: Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007, 25:23–28.
    CAS PubMed Google Scholar
  23. Vassallo R, Matteson E, Thomas CF Jr: Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002, 122:1093–1096.
    Article PubMed Google Scholar
  24. Raghu G, Brown KK, Costabel U, et al.: Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178:948–955.
    Article CAS PubMed Google Scholar
  25. Kohno N, Awaya Y, Oyama T, et al.: KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993, 148:637–642.
    CAS PubMed Google Scholar
  26. Honda Y, Kuroki Y, Matsuura E, et al.: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995, 152:1860–1866.
    CAS PubMed Google Scholar
  27. •• Fertig N, Domsic RT, Rodriguez-Reyna T, et al.: Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009, 61:958–965. This article describes a new autoantibody associated with severe progressive lung fibrosis in SSc and compares its frequency with that of other ILD-associated circulating autoantibodies.
    Article CAS PubMed Google Scholar
  28. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al.: Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006, 33:1600–1605.
    PubMed Google Scholar
  29. Kakugawa T, Yokota S-I, Mukae H, et al.: High serum concentrations of autoantibodies to HSP47 in nonspecific interstitial pneumonia compared with idiopathic pulmonary fibrosis. BMC Pulm Med 2008, 8:23.
    Article PubMed Google Scholar
  30. Yang Y, Fujita J, Bandoh S, et al.: Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Clin Exp Immunol 2002, 128:169–174.
    Article CAS PubMed Google Scholar
  31. • Feghali-Bostwick CA, Tsai CG, Valentine VG, et al.: Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007, 179:2592–2599. Research described in this manuscript demonstrates that, as with SSc, IPF has features of autoimmune diseases.
    CAS PubMed Google Scholar
  32. Fujita J, Dobashi N, Ohtsuki Y, et al.: Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung 1999, 177:311–319.
    Article CAS PubMed Google Scholar
  33. Arnett FC, Cho M, Chatterjee S, et al.: Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001, 44:1359–1362.
    Article CAS PubMed Google Scholar
  34. Englert H, Small-McMahon J, Chambers P, et al.: Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999, 29:36–41.
    CAS PubMed Google Scholar
  35. •• Feghali-Bostwick C, Medsger TA Jr, Wright TM: Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003, 48:1956–1963. This article describes the only study examining concordance for SSc and the presence of antinuclear antibodies in twins.
    Article PubMed Google Scholar
  36. Zhou X, Tan FK, Xiong M, et al.: Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum 2005, 52:3305–3314.
    Article CAS PubMed Google Scholar
  37. Dieude P, Guedj M, Wipff J, et al.: STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009, 60:2472–2479.
    Article CAS PubMed Google Scholar
  38. Coward WR, Watts K, Feghali-Bostwick CA, et al.: Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol 2009, 29:4325–4339.
    Article CAS PubMed Google Scholar
  39. Glenisson W, Castronovo V, Waltregny D: Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta 2007, 1773:1572–1582.
    Article CAS PubMed Google Scholar
  40. • Wang Y, Fan PS, Kahaleh B: Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006, 54:2271–2279. This is the first published report of altered methylation in SSc.
    Article CAS PubMed Google Scholar
  41. • Sanders YY, Pardo A, Selman M, et al.: Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008, 39:610–618. This is the first published report of altered methylation in IPF.
    Article CAS PubMed Google Scholar
  42. Armanios MY, Chen JJ, Cogan JD, et al.: Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356:1317–1326.
    Article CAS PubMed Google Scholar
  43. Tsakiri KD, Cronkhite JT, Kuan PJ, et al.: Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007, 104:7552–7557.
    Article CAS PubMed Google Scholar
  44. Ohtsuka T, Yamakage A, Yamazaki S: The polymorphism of telomerase RNA component gene in patients with systemic sclerosis. Br J Dermatol 2002, 147:250–254.
    Article CAS PubMed Google Scholar
  45. Katayama Y, Kohriyama K: Telomerase activity in peripheral blood mononuclear cells of systemic connective tissue diseases. J Rheumatol 2001, 28:288–291.
    CAS PubMed Google Scholar
  46. • Denton CP, Merkel PA, Furst DE, et al.: Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007, 56:323–333. This study demonstrates that although TGF-β is considered a central mediator of fibrosis in SSc and related diseases, a TGF-β-blocking antibody failed to show efficacy in a clinical trial.
    Article CAS PubMed Google Scholar
  47. Aston C, Jagirdar J, Lee TC, et al.: Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995, 151:1597–1603.
    CAS PubMed Google Scholar
  48. Hsu E, Feghali-Bostwick CA: Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways. Am J Pathol 2008, 172:1580–1590.
    Article CAS PubMed Google Scholar
  49. Pilewski JM, Liu L, Henry AC, et al.: Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005, 166:399–407.
    CAS PubMed Google Scholar
  50. •• Yasuoka H, Larregina AT, Yamaguchi Y, Feghali-Bostwick CA: Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. Open Rheumatol J 2008, 2:17–22. This article describes the use of an ex vivo human skin organ culture model to assess the effect of fibrotic and antifibrotic molecules, minimize the use of animal models, and render findings more directly applicable to human disease.
    Article CAS PubMed Google Scholar

Download references